Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.48 |
| ▸ | CHUK | O15111 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | PAK4 | O96013 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | LTK | P29376 | 1/20 | 0.48 |
| ▸ | GRK5 | P34947 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1327972 | 0.89 | IKBKB (0.47) | IKBKBCHUKJAK2ROCK1DAPK3 | |
| SCHEMBL1328084 | 0.84 | JAK2 (0.43) | IKBKBCHUKJAK2ROCK1DAPK3 | |
| SCHEMBL1327987 | 0.84 | PTK2 (0.43) | IKBKBCHUKJAK2ROCK1DAPK3 | |
| SCHEMBL1328116 | 0.82 | NUDT1 (0.44) | IKBKBCHUKJAK2ROCK1DAPK3 | |
| SCHEMBL1328095 | 0.80 | IKBKB (0.63) | IKBKBCHUKJAK2ROCK1DAPK3 | |
| SCHEMBL1328341 | 0.77 | BTK (0.49) | IKBKBCHUKJAK2ROCK1DAPK3 | |
| SCHEMBL27847620 | 0.77 | NUDT1 (0.38) | IKBKBCHUKJAK2ROCK1DAPK3 | |
| SCHEMBL12127459 | 0.77 | IKBKB (0.59) | IKBKBCHUKJAK2ROCK1DAPK3 | |
| SCHEMBL1328119 | 0.77 | NUDT1 (0.37) | IKBKBCHUKJAK2ROCK1DAPK3 | |
| SCHEMBL1329344 | 0.77 | ANO1 (0.41) | IKBKBCHUKJAK2ROCK1DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | claimed |
| CN-101918079-A | Protein kinase inhibitors and use thereof | MERCK SERONO SA | 2010-12-15 | — | — | CN | claimed |
| EP-2231282-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-09-29 | — | — | EP | claimed |
| WO-2009094123-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-07-30 | — | — | WO | claimed |
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
| CN-101918079-A | Protein kinase inhibitors and use thereof | MERCK SERONO SA | 2010-12-15 | — | — | CN | disclosed |
| WO-2009094123-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP3K19, MAP3K20, MAP3K1 | IKBKB 436/4885CHUK 212/4885JAK2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.